Emerald Advisers LLC Acquires 89,088 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Emerald Advisers LLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 57.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 244,633 shares of the company’s stock after purchasing an additional 89,088 shares during the period. Emerald Advisers LLC’s holdings in Keros Therapeutics were worth $3,873,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. increased its holdings in Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after acquiring an additional 1,033 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Keros Therapeutics by 11.3% in the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after acquiring an additional 1,100 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after acquiring an additional 1,372 shares in the last quarter. Point72 DIFC Ltd increased its holdings in Keros Therapeutics by 9.8% in the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after acquiring an additional 1,715 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Keros Therapeutics by 59.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock worth $312,000 after acquiring an additional 1,994 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Performance

KROS stock opened at $11.22 on Monday. The firm has a fifty day moving average price of $11.18 and a 200 day moving average price of $35.80. Keros Therapeutics, Inc. has a fifty-two week low of $9.78 and a fifty-two week high of $72.37. The firm has a market cap of $455.11 million, a PE ratio of -2.15 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. On average, equities analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.